Clinical Trials
Clinerion partners with Eugen to expand Patient Network Explorer coverage to patients and hospitals in Uruguay
Eugen, a clinical development service provider based in Uruguay, will support Clinerion’s expansion by promoting hospitals in the country to join Patient Network Explorer (PNEx), adding to the platform true global representativeness.
They will use PNEx to provide clients with...
Clinical Trials
ImmuPharma signs agreement with Avion for Lupuzor
UK-based pharmaceutical company ImmuPharma has signed a licensing and development agreement with US-based Avion Pharmaceuticals for Lupuzor, a peptide therapeutic and a first-in-class autophagy immunomodulator for auto-immune disease systemic lupus erythematosus (SLE or lupus).
Under the agreement, the two firms...
Clinical Trials
Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials
The global pharmaceutical company and service partner Inceptua Group (previously Multipharma GmbH) and Bendalis GmbH – German manufacturer of generic oncology drugs and special therapeutic agents, announce the signing of an exclusive clinical trial supply agreement for oncology generics.
Through...
Clinical Trials
ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer
ERYTECH Pharma a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that the full results from its Phase 2b trial evaluating eryaspase in metastatic pancreatic cancer are now published online in...
Clinical Trials
Anixa Biosciences collaborates with Urology Centers of Alabama on Cchek early prostate cancer detection study
Anixa Biosciences, Inc., a biotechnology company, announced a collaboration with Urology Centers of Alabama (UCA) in the Cchek early prostate cancer detection study. UCA will provide patient samples in Anixa's ongoing study, including support of clinical validation of Anixa's...
Clinical Trials
Biogen completes enrollment in phase 3 STAR study of gene therapy timrepigene emparvovec to treat inherited retinal disorder
Biogen Inc, a global biotechnology company, announced the enrollment of the last patient in the global phase 3 STAR clinical study, which is evaluating the investigational gene therapy timrepigene emparvovec (BIIB111/AAV2-REP1) for the treatment of choroideremia (CHM). CHM is...
Clinical Trials
CRISPR Therapeutics, Vertex Report First Data from Trials of Gene-Editing Treatment CTX001
CRISPR Therapeutics and Vertex Pharmaceuticals reported preliminary, mostly-positive safety and efficacy data from the first two patients enrolled in two Phase I/II trials assessing their CRISPR/Cas9 gene-edited therapy CTX001 for a pair of blood disorders—the first clinical trial of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.